

Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients ASTRAL-5


Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients

ASTRAL-5: Study Features

- **Design:** Single-arm, open-label, multicenter, phase 3 trial of sofosbuvir-velpatasvir in HIV-HCV coinfecting treatment-naïve and treatment-experienced patients with genotypes 1-6 HCV
- **Setting:** Multiple sites in US
- **Entry Criteria**
 - Chronic HCV GT 1-6
 - Age ≥ 18 years
 - HIV coinfection
 - CD4 count ≥ 100 cells/mm³ and HIV RNA ≤ 50 copies/mL
 - On stable ART for ≥ 8 weeks
 - Prior treatment failure allowed (but no prior NS5A or NS5B)
 - Patients with compensated cirrhosis allowed
- **Primary End Point:** SVR12

Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients

ASTRAL-5: Study Design



Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients

ASTRAL-5: Participants

Baseline Characteristic	Sofosbuvir-Velpatasvir (n = 106)
Age, mean, years (range)	54 (25-72)
Male, n (%)	91 (86)
Black race, n (%)	48 (45)
HCV genotype, n (%)	
1a	66 (62)
1b	12 (11)
2	11 (10)
3	12 (11)
4	5 (5)
IL28B non-CC, n (%)	82 (77)
Mean HCV RNA, log ₁₀ IU/mL (range)	6.3 (5.0-7.4)
Cirrhosis, n (%)	19 (18)
Treatment experienced, n (%)	31 (29)

Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients


ASTRAL-5: Participants

HIV Baseline Characteristics	Sofosbuvir-Velpatasvir (n = 106)
Mean CD4 cell count, (range)	598 (183-1513)
Nucleos(t)ide pair	
TDF with boosted agent (Ritonavir or Cobicistat)	56 (53)
TDF without boosted agent	35 (33)
Abacavir-lamivudine	15 (14)
Other antiretroviral agent(s)	
Protease Inhibitor (DRV, LPV, or ATV)	50 (47)
NNRTI (RPV)	13 (12)
Integrase inhibitor (RAL or EVG)	36 (34)
Other (>1 of above classes)	7 (7)
Abbreviations: TDF, Tenofovir disoproxil fumarate; RTV, ritonavir; DRV, darunavir; LPV, lopinavir; ATV, atazanavir; RPV, rilpivirine; RAL, raltegravir; EVG, elvitegravir	

Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients

ASTRAL-5: Results


SVR12 Results by Genotype



Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients

ASTRAL-5: Results


SVR12 Results by Genotype



Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients

ASTRAL-5: Results

SVR12 Results by Treatment Experience and Cirrhosis Status




Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients


ASTRAL-5: Resistance

Baseline Resistance-Associated Variants (RAVs)

■ No NS5A RAVs ■ NS5A RAVs



Response to Treatment (SVR12)



Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients

ASTRAL-5: Tenofovir Pharmacokinetics

Mean (%CV) PK Parameters of Tenofovir by Boosted or Unboosted ART Regimen

Tenofovir PK Parameter	Sofosbuvir-Velpatasvir + Unboosted Tenofovir DF-Containing Regimens (n = 35)	Sofosbuvir-Velpatasvir + Boosted Tenofovir DF-Containing Regimens (n = 56)
AUC _{tau} (h•ng/mL)	3590 (23.2)	3740 (26.3)
C _{max} (ng/mL)	319 (26.4)	351 (30.8)
C _{tau} (ng/mL)	91.2 (37.9)	92.9 (41.4)

Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients

ASTRAL-5: Adverse Events

Adverse Event (AE), n (%)	Sofosbuvir-Velpatasvir (n = 106)
Discontinuation due to AE	2 (2)
Serious AEs	2 (2)
Deaths	0
Any AE in >5% of patients	
Fatigue	26 (25)
Headache	14 (13)
Arthralgia	9 (8)
Upper respiratory tract infection	9 (8)
Diarrhea	9 (8)
Insomnia	7 (7)
Nausea	7 (7)
<p>The majority of AEs were mild in severity (grade 1 or 2) No patient with confirmed on-treatment HIV virologic breakthrough</p>	

Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients

ASTRAL-5: Conclusions

Conclusions: “Sofosbuvir-velpatasvir for 12 weeks was safe and provided high rates of SVR12 in patients coinfecting with HCV and HIV-1.”

Acknowledgments

Hepatitis C Online is funded by a cooperative agreement from the Centers for Disease Control and Prevention (CDC-RFA- PS21-2105). This project is led by the University of Washington Infectious Diseases Education and Assessment (IDEA) Program.



The contents in this presentation are those of the author(s) and do not necessarily represent the official position of views of, nor an endorsement, by the Centers for Disease Control and Prevention.